Puma Biotechnology | PBYI - Current Liabilities


Puma Biotechnology reported $82.73M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amgen USD 24.96B 534M Mar/2026
Biogen USD 3B 350.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Esperion Therapeutics USD 300.36M 451K Mar/2026
Exelixis USD 370.98M 34.67M Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
MacroGenics USD 95.94M 52.82M Mar/2026
Moderna USD 2.4B 408M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Takeda JPY 2.43T 180.65B Mar/2026
TG Therapeutics USD 187.11M 33.35M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026